IgA Nephropathy Market Insights: Prevalence, Market Size, and Future Outlook (2034)


IgA nephropathy (IgAN), also known as Berger’s disease, is a chronic kidney disease characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, leading to progressive kidney damage. It often presents with hematuria, proteinuria, and sometimes hypertension, ultimately increasing the risk of end-stage renal disease (ESRD). Despite its prevalence, effective targeted therapies for IgAN remain limited, driving research and development in this domain.

IgA nephropathy Epidemiology Overview

Globally, IgAN is a leading cause of primary glomerulonephritis, with significant regional variability in its incidence and prevalence. In the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, the prevalence of IgAN is estimated to be approximately 5 cases per 100,000 population in 2023. Japan reports the highest prevalence due to increased screening and diagnosis. In contrast, lower detection rates in Western countries result in fewer reported cases, though the actual burden may be underestimated.

Key IgA nephropathy Companies In The Market Landscape:

The key IgA nephropathy companies in the market include - Calliditas Therapeutics AB, Travere Therapeutics, Inc, Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., and others.

IgA nephropathy Market Insights

The IgAN market is poised for growth with increasing disease awareness and the advancement of targeted therapies. Current management options include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for supportive care, while emerging therapies like targeted immunosuppressants and complement inhibitors are expected to revolutionize treatment paradigms.

IgA nephropathy Market Forecast and Growth Drivers

The IgAN market is projected to grow at a significant compound annual growth rate (CAGR) from 2023 to 2034, driven by the anticipated approval and uptake of novel therapies. These include drugs targeting the complement pathway, B-cell modulation, and endothelin receptor antagonists. With multiple late-stage clinical trials demonstrating promise, the competitive landscape is expected to expand considerably.

Conclusion:

By 2034, the IgAN market size across the 7MM is forecasted to surpass USD 4 billion. This growth reflects increasing investment in drug development, heightened disease awareness, and improved diagnostic techniques. The pipeline therapies are poised to address significant unmet needs, offering hope to patients and shaping the future of IgAN treatment.

Latest Reports Offered By DelveInsight:

Latest Blogs Offered By DelveInight:

Comments

Post a Comment

Popular posts from this blog

Brachytherapy Devices Market Report Highlights and Market Forecast for the Study Period (2019-2027)

Image
The Brachytherapy Devices market is anticipated to surge due to a number of factors, including an increase in the geriatric population, an increase in the prevalence of chronic diseases, an increase in fitness and physical activity awareness, and an increase in regulatory approval for Brachytherapy Devices.   Brachytherapy Devices Medical Devices Market report from DelveInsight provides an in-depth analysis of Brachytherapy Devices, as well as historical and forecasted market trends in the global Brachytherapy Devices market ( North-America, Europe, Asia Pacific and Rest of the world ). What are Brachytherapy Devices? Placing radioactive material into the body is a practice known as brachytherapy. It is a form of internal radiation therapy in which the patient is given radiation-containing seeds, ribbons, or capsules that are injected into or close to the tumor. Only one particular area of the body is treated by brachytherapy, which is a local treatment. Cancers of the head and ne...
Read more

RSVPreF and Beyond: The Next Generation of Respiratory Syncytial Virus Treatment

Image
Respiratory Syncytial Virus (RSV) is a common viral infection that affects the respiratory tract, particularly in young children and older adults. The burden of Respiratory Syncytial Virus-related illnesses is significant, leading to millions of hospitalizations worldwide each year. As a result, the respiratory syncytial virus treatment market has emerged as a complex and lucrative space, with billions of dollars at stake. In this blog post, we will explore the current therapies available for RSV, the challenges they face, and the promising upcoming therapies. Current Respiratory Syncytial Virus Therapies, their Challenges, and Upcoming Therapies The current treatment options for RSV primarily focus on supportive care, including adequate hydration, oxygen supplementation, and antipyretics to reduce fever. However, these approaches do not directly target the virus itself, leaving a significant gap in effective treatment. The challenges associated with developing RSV-specific therapie...
Read more

Navigating the Changing Tides of the Ocular Implants Market

Image
The ocular implants market is a rapidly growing industry that involves the use of medical devices to improve vision and treat eye conditions. Ocular implants are artificial devices that are placed within the eye to replace or supplement natural eye structures. In this blog, we will discuss what ocular implants are, their major benefits and drawbacks, regional market assessment, key companies in the ocular implants market, and future market assessment. What are Ocular Implants? Ocular implants are medical devices that are designed to improve vision and treat eye conditions such as cataracts , glaucoma , diabetic retinopathy , and macular degeneration. These devices are made of various materials, including silicone, acrylic, and polymethyl methacrylate (PMMA), and are surgically implanted into the eye. Ocular Implants – Major Benefits and Drawbacks The major benefits of ocular implants are improved vision and reduced dependence on glasses or contact lenses. They can also treat various ...
Read more